In a Phase II study involving retatrutide, a triple agonist of glucose‐dependent insulinotropic polypeptide (GIP), GLP1, and glucagon, patients with obesity experienced a 25% reduction in weight.34 Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.